List of Tables
Table 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Immunomodulators
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Disorder Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Neurodegenerative Disorder Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2019-2024)
Table 11. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2025-2030)
Table 13. Neurodegenerative Disorder Therapeutics Market Trends
Table 14. Neurodegenerative Disorder Therapeutics Market Drivers
Table 15. Neurodegenerative Disorder Therapeutics Market Challenges
Table 16. Neurodegenerative Disorder Therapeutics Market Restraints
Table 17. Global Neurodegenerative Disorder Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Neurodegenerative Disorder Therapeutics Market Share by Players (2019-2024)
Table 19. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2023)
Table 20. Ranking of Global Top Neurodegenerative Disorder Therapeutics Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Disorder Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Disorder Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2019-2024)
Table 28. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2025-2030)
Table 30. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2019-2024)
Table 32. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2025-2030)
Table 34. North America Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 49. Biogen, Inc. Company Detail
Table 50. Biogen, Inc. Business Overview
Table 51. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product
Table 52. Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 53. Biogen, Inc. Recent Development
Table 54. Pfizer, Inc. Company Detail
Table 55. Pfizer, Inc. Business Overview
Table 56. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product
Table 57. Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 58. Pfizer, Inc. Recent Development
Table 59. Novartis AG Company Detail
Table 60. Novartis AG Business Overview
Table 61. Novartis AG Neurodegenerative Disorder Therapeutics Product
Table 62. Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 63. Novartis AG Recent Development
Table 64. Sanofi S.A. Company Detail
Table 65. Sanofi S.A. Business Overview
Table 66. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product
Table 67. Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 68. Sanofi S.A. Recent Development
Table 69. Teva Pharmaceutical Industries Ltd. Company Detail
Table 70. Teva Pharmaceutical Industries Ltd. Business Overview
Table 71. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product
Table 72. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 73. Teva Pharmaceutical Industries Ltd. Recent Development
Table 74. UCB S.A. Company Detail
Table 75. UCB S.A. Business Overview
Table 76. UCB S.A. Neurodegenerative Disorder Therapeutics Product
Table 77. UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 78. UCB S.A. Recent Development
Table 79. F. Hoffmann- La Roche Ltd. Company Detail
Table 80. F. Hoffmann- La Roche Ltd. Business Overview
Table 81. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product
Table 82. F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 83. F. Hoffmann- La Roche Ltd. Recent Development
Table 84. H. Lundbeck Company Detail
Table 85. H. Lundbeck Business Overview
Table 86. H. Lundbeck Neurodegenerative Disorder Therapeutics Product
Table 87. H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 88. H. Lundbeck Recent Development
Table 89. Merck KGaA Company Detail
Table 90. Merck KGaA Business Overview
Table 91. Merck KGaA Neurodegenerative Disorder Therapeutics Product
Table 92. Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 93. Merck KGaA Recent Development
Table 94. GlaxoSmithKline PLC Company Detail
Table 95. GlaxoSmithKline PLC Business Overview
Table 96. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product
Table 97. GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 98. GlaxoSmithKline PLC Recent Development
Table 99. AbbVie Inc. Company Detail
Table 100. AbbVie Inc. Business Overview
Table 101. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product
Table 102. AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 103. AbbVie Inc. Recent Development
Table 104. Bristol Myers Squibb Company Company Detail
Table 105. Bristol Myers Squibb Company Business Overview
Table 106. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product
Table 107. Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 108. Bristol Myers Squibb Company Recent Development
Table 109. Boehringer Ingeiheim International GmbH Company Detail
Table 110. Boehringer Ingeiheim International GmbH Business Overview
Table 111. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product
Table 112. Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 113. Boehringer Ingeiheim International GmbH Recent Development
Table 114. Bayer AG Company Detail
Table 115. Bayer AG Business Overview
Table 116. Bayer AG Neurodegenerative Disorder Therapeutics Product
Table 117. Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 118. Bayer AG Recent Development
Table 119. Eisai Co., Ltd Company Detail
Table 120. Eisai Co., Ltd Business Overview
Table 121. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product
Table 122. Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 123. Eisai Co., Ltd Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disorder Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Neurodegenerative Disorder Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Immunomodulators Features
Figure 4. Interferons Features
Figure 5. Decarboxylase Inhibitors Features
Figure 6. Dopamine Agonists Features
Figure 7. Others Features
Figure 8. Global Neurodegenerative Disorder Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2023 VS 2030
Figure 10. Multiple Sclerosis Case Studies
Figure 11. Parkinson'S Disease Case Studies
Figure 12. Alzheimer'S Disease Case Studies
Figure 13. Spinal Muscular Atrophy Case Studies
Figure 14. Huntington Disease Case Studies
Figure 15. Other Neurodegenerative Disorders Case Studies
Figure 16. Neurodegenerative Disorder Therapeutics Report Years Considered
Figure 17. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 18. Global Neurodegenerative Disorder Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Neurodegenerative Disorder Therapeutics Market Share by Region: 2023 VS 2030
Figure 20. Global Neurodegenerative Disorder Therapeutics Market Share by Players in 2023
Figure 21. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2023)
Figure 22. The Top 10 and 5 Players Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2023
Figure 23. North America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Neurodegenerative Disorder Therapeutics Market Share by Country (2019-2030)
Figure 25. United States Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Canada Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Neurodegenerative Disorder Therapeutics Market Share by Country (2019-2030)
Figure 29. Germany Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Region (2019-2030)
Figure 37. China Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Japan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. South Korea Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. India Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Australia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Neurodegenerative Disorder Therapeutics Market Share by Country (2019-2030)
Figure 45. Mexico Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Brazil Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Share by Country (2019-2030)
Figure 49. Turkey Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Biogen, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 52. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 53. Novartis AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 54. Sanofi S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 55. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 56. UCB S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 57. F. Hoffmann- La Roche Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 58. H. Lundbeck Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 59. Merck KGaA Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 60. GlaxoSmithKline PLC Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 61. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 62. Bristol Myers Squibb Company Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 63. Boehringer Ingeiheim International GmbH Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 64. Bayer AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 65. Eisai Co., Ltd Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2019-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed